Drug Discovery Case History 1. Introduction

First Page		Document Content
Date: 2013-07-01 10:35:04 Oncogenes Tyrosine kinase receptors Organofluorides Proteins Crizotinib ALK inhibitor Anaplastic lymphoma kinase Protein kinase inhibitor Tyrosine kinase Biology Cell biology Lung cancer		Drug Discovery Case History 1. Introduction Add to Reading List Source URL: www.brimr.org Download Document from Source Website File Size: 640,77 KB Share Document on Facebook

	PDF Document DocID: 1npVD - View Document
	Early Stage researcher (ESR) PhD Projects ESR 1 Investigation of the nuclear functions of ALK Duration: 3 years Start: before August 2016 DocID: 1mHtD - View Document
	Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer PosterHendrik-Tobias Arkenau,1 Jasgit C. Sachdev DocID: 1lzQ3 - View Document
	Cambridges Healthtech Institute´s 22th International Molecular Med Tri-Con 2015 San Francisco, Feb 2015 Enumeration and ALK investigation of circulating tumor cells in non-small cell lung cancer (NSCLC) patients using a DocID: 1gnav - View Document
	Cambridges Healthtech Institute´s 22th International Molecular Med Tri-Con 2015 San Francisco, Feb 2015 Enumeration and ALK investigation of circulating tumor cells in non-small cell lung cancer (NSCLC) patients using a DocID: 1abrR - View Document